Rajesh Upadhyay, Navin K Soni, Ashwin A Kotamkar, Azra Naseem, Aaditi Phadke, Shreshth Nayar, Shailesh Pallewar, Parvan Shetty, Ashish Mungantiwar, Sunil Jaiswal, Amit Qamra
{"title":"大剂量泮托拉唑治疗胃食管反流病:需求、证据、指南和我们的经验。","authors":"Rajesh Upadhyay, Navin K Soni, Ashwin A Kotamkar, Azra Naseem, Aaditi Phadke, Shreshth Nayar, Shailesh Pallewar, Parvan Shetty, Ashish Mungantiwar, Sunil Jaiswal, Amit Qamra","doi":"10.5005/jp-journals-10018-1426","DOIUrl":null,"url":null,"abstract":"<p><p>Gastroesophageal reflux disease (GERD) has a pooled prevalence of 15.2% in India with varying presentation in different subset of patients. The approach towards the management of GERD includes use of monotherapy or a combination of OTCs like antacids and/or prescription drugs like H2 receptor antagonists and proton pump inhibitors (PPI). Better efficacy and safety profile of PPIs have contributed to its wide spread use as compared with other drugs for the same indication. Among PPIs, most of the healthcare professionals prefer to prescribe pantoprazole in India. Standard dose of Pantoprazole (40 mg) is unable to meet the needs in case of extraesophageal symptoms, partial responders, patients with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs), or severe presentation in cases of overweight/obese patients. Multiple guidelines recommend doubling the dose of PPI in such cases. Twice daily dosing of PPI may reduce compliance. Thus, there is a need for a higher dose of Pantoprazole (80 mg) to be prescribed once daily in these cases so that improved compliance leads to better outcomes. The use of dual release Pantoprazole 80 mg may help to improve compliance and also enhance the time for which acid suppression takes place. In this review, we discuss the use of higher dose PPI based on scientific evidence and experience of clinicians for the same.</p><p><strong>How to cite this article: </strong>Upadhyay R, Soni NK, Kotamkar AA, <i>et al</i>. High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience. Euroasian J Hepato-Gastroenterol 2024;14(1):86-91.</p>","PeriodicalId":516317,"journal":{"name":"Euroasian journal of hepato-gastroenterology","volume":"14 1","pages":"86-91"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249892/pdf/","citationCount":"0","resultStr":"{\"title\":\"High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience.\",\"authors\":\"Rajesh Upadhyay, Navin K Soni, Ashwin A Kotamkar, Azra Naseem, Aaditi Phadke, Shreshth Nayar, Shailesh Pallewar, Parvan Shetty, Ashish Mungantiwar, Sunil Jaiswal, Amit Qamra\",\"doi\":\"10.5005/jp-journals-10018-1426\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Gastroesophageal reflux disease (GERD) has a pooled prevalence of 15.2% in India with varying presentation in different subset of patients. The approach towards the management of GERD includes use of monotherapy or a combination of OTCs like antacids and/or prescription drugs like H2 receptor antagonists and proton pump inhibitors (PPI). Better efficacy and safety profile of PPIs have contributed to its wide spread use as compared with other drugs for the same indication. Among PPIs, most of the healthcare professionals prefer to prescribe pantoprazole in India. Standard dose of Pantoprazole (40 mg) is unable to meet the needs in case of extraesophageal symptoms, partial responders, patients with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs), or severe presentation in cases of overweight/obese patients. Multiple guidelines recommend doubling the dose of PPI in such cases. Twice daily dosing of PPI may reduce compliance. Thus, there is a need for a higher dose of Pantoprazole (80 mg) to be prescribed once daily in these cases so that improved compliance leads to better outcomes. The use of dual release Pantoprazole 80 mg may help to improve compliance and also enhance the time for which acid suppression takes place. In this review, we discuss the use of higher dose PPI based on scientific evidence and experience of clinicians for the same.</p><p><strong>How to cite this article: </strong>Upadhyay R, Soni NK, Kotamkar AA, <i>et al</i>. High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience. Euroasian J Hepato-Gastroenterol 2024;14(1):86-91.</p>\",\"PeriodicalId\":516317,\"journal\":{\"name\":\"Euroasian journal of hepato-gastroenterology\",\"volume\":\"14 1\",\"pages\":\"86-91\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249892/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Euroasian journal of hepato-gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5005/jp-journals-10018-1426\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Euroasian journal of hepato-gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10018-1426","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
胃食管反流病(GERD)在印度的总发病率为 15.2%,不同亚群的患者表现各异。治疗胃食管反流病的方法包括单药治疗或联合使用抗酸剂等非处方药和/或 H2 受体拮抗剂和质子泵抑制剂(PPI)等处方药。与用于相同适应症的其他药物相比,质子泵抑制剂具有更好的疗效和安全性,因此被广泛使用。在 PPIs 中,印度大多数医疗保健专业人员更倾向于处方泮托拉唑。泮托拉唑的标准剂量(40 毫克)无法满足食管外症状、部分反应者、同时使用非甾体抗炎药(NSAIDs)的患者或超重/肥胖患者的严重症状。多种指南建议在这种情况下加倍 PPI 的剂量。每天两次服用 PPI 可能会降低依从性。因此,有必要在这些病例中每天一次处方较大剂量的泮托拉唑(80 毫克),以提高依从性,从而取得更好的疗效。使用双释放泮托拉唑(80 毫克)可能有助于提高依从性,并延长抑酸时间。在这篇综述中,我们将根据科学证据和临床医生的经验,讨论如何使用更大剂量的 PPI:Upadhyay R, Soni NK, Kotamkar AA, et al:需求、证据、指南和我们的经验。Euroasian J Hepato-Gastroenterol 2024;14(1):86-91.
High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience.
Gastroesophageal reflux disease (GERD) has a pooled prevalence of 15.2% in India with varying presentation in different subset of patients. The approach towards the management of GERD includes use of monotherapy or a combination of OTCs like antacids and/or prescription drugs like H2 receptor antagonists and proton pump inhibitors (PPI). Better efficacy and safety profile of PPIs have contributed to its wide spread use as compared with other drugs for the same indication. Among PPIs, most of the healthcare professionals prefer to prescribe pantoprazole in India. Standard dose of Pantoprazole (40 mg) is unable to meet the needs in case of extraesophageal symptoms, partial responders, patients with concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs), or severe presentation in cases of overweight/obese patients. Multiple guidelines recommend doubling the dose of PPI in such cases. Twice daily dosing of PPI may reduce compliance. Thus, there is a need for a higher dose of Pantoprazole (80 mg) to be prescribed once daily in these cases so that improved compliance leads to better outcomes. The use of dual release Pantoprazole 80 mg may help to improve compliance and also enhance the time for which acid suppression takes place. In this review, we discuss the use of higher dose PPI based on scientific evidence and experience of clinicians for the same.
How to cite this article: Upadhyay R, Soni NK, Kotamkar AA, et al. High Dose Pantoprazole for Gastroesophageal Reflux Disease: Need, Evidence, Guidelines and Our Experience. Euroasian J Hepato-Gastroenterol 2024;14(1):86-91.